101 related articles for article (PubMed ID: 6894108)
1. In vivo effects in mice produced by a 3'-branched homologue of alpha-2'-deoxythioguanosine.
LePage GA; Banks PA; Noujaim MJ; Buzzell GR
Cancer Chemother Pharmacol; 1980; 5(2):127-31. PubMed ID: 6894108
[TBL] [Abstract][Full Text] [Related]
2. Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose.
Acton EM; Goerner RN; Uh HS; Ryan KJ; Henry DW; Cass CE; LePage GA
J Med Chem; 1979 May; 22(5):518-25. PubMed ID: 582321
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and toxicology of alpha-2'-deoxythioguanosine in cancer patients.
LePage GA; Khaliq A
Cancer Treat Rep; 1979 Jan; 63(1):53-7. PubMed ID: 421233
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA chain growth by alpha-2'-deoxythioguanosine.
Tamaoki T; LePage GA
Cancer Res; 1975 Apr; 35(4):1103-7. PubMed ID: 1172936
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man.
Lu K; Benvenuto JA; Bodey GP; Gottlieb JA; Rosenblum MG; Loo TL
Cancer Chemother Pharmacol; 1982; 8(1):119-23. PubMed ID: 7094197
[TBL] [Abstract][Full Text] [Related]
6. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA.
Krynetskaia NF; Krynetski EY; Evans WE
Mol Pharmacol; 1999 Oct; 56(4):841-8. PubMed ID: 10496969
[TBL] [Abstract][Full Text] [Related]
7. Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog.
Loo TL; Lu K; Benvenuto JA; Rosenblum MG
Cancer Chemother Pharmacol; 1981; 6(2):131-6. PubMed ID: 7307231
[TBL] [Abstract][Full Text] [Related]
8. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide formation from alpha- and beta-2'-deoxythioguanosine in extracts of murine and human tissues.
Peery A; LePage GA
Cancer Res; 1969 Mar; 29(3):617-23. PubMed ID: 5818457
[No Abstract] [Full Text] [Related]
10. Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.
Higgins GR; Jamin DC; Shore NA; Momparler R; Hartman G; Siegel SE
Cancer Treat Rep; 1985 Jun; 69(6):699-701. PubMed ID: 3860294
[TBL] [Abstract][Full Text] [Related]
11. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
12. 2' -DEOXYTHIOGUANOSINE AND RELATED NUCLEOSIDES.
IWAMOTO RH; ACTON EM; GOODMAN L
J Med Chem; 1963 Nov; 6():684-8. PubMed ID: 14184926
[No Abstract] [Full Text] [Related]
13. [Antiproliferative action of 5'-S-isobutyladenosine in vitro and in vivo on normal and neoplastic mouse cells].
Mironova SB; Lidak MIu; Fedorov NA; Zarinia DE
Biull Eksp Biol Med; 1984 Jun; 97(6):708-10. PubMed ID: 6611176
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-chlorethyl)-1-nitrosourea: a Phase II-III study of the Eastern Cooperative Oncology Group (EST 4273).
Douglass HO; Lavin PT; Woll J; Conroy JF; Carbone P
Cancer; 1978 Dec; 42(6):2538-45. PubMed ID: 365312
[TBL] [Abstract][Full Text] [Related]
15. Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
Momparler RL; Momparler LF; Samson J
Int J Cancer; 1982 Sep; 30(3):361-64. PubMed ID: 6182115
[TBL] [Abstract][Full Text] [Related]
16. Methanol exposure does not lead to accumulation of oxidative DNA damage in bone marrow and spleen of mice, rabbits or primates.
McCallum GP; Siu M; Ondovcik SL; Sweeting JN; Wells PG
Mol Carcinog; 2011 Mar; 50(3):163-72. PubMed ID: 21104990
[TBL] [Abstract][Full Text] [Related]
17. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
Myers CE; Young RC; Chabner BA
Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
[TBL] [Abstract][Full Text] [Related]
18. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
[TBL] [Abstract][Full Text] [Related]
19. Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.
Panasci LC; Green D; Schein PS
J Clin Invest; 1979 Oct; 64(4):1103-11. PubMed ID: 158033
[TBL] [Abstract][Full Text] [Related]
20. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs.
Coulthard SA; Hogarth LA; Little M; Matheson EC; Redfern CP; Minto L; Hall AG
Mol Pharmacol; 2002 Jul; 62(1):102-9. PubMed ID: 12065760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
